Zosano Pharma reports positive phase 2 results for glucagon patch device for severe hypoglycaemia.
Zosano reported positive phase 2 results for its glucagon patch for potential treatment of severe hypoglycaemia (Zosano press release, 13 October 2015)?.
The trial was conducted in 16 T1DM patients, receiving glucagon by means of Zosano's microneedle patch system or Novo Nordisk's GlucaGen® hypokit.
Following insulin-induced hypoglycaemia, the glucagon patch normalised blood sugar in all subjects. Time to glucose response was similar to injectable glucagon. A pivotal phase 3 trial could commence in 2016, according to the company. With the Zosano patch, glucagon is administered to the patient by pressing the device against the skin, with no need for reconstitution as for the two marketed glucagon hypokits from Eli Lilly and Novo Nordisk. Planning to enter phase 3, Zosano is a contender for bringing a simplified hypoglycaemia rescue solution to the market.
Bei dem Cash-Burn brauchen die bald schon wieder Kohle. In Q2 steht nochmal ein Milestone an, der den Kurs beflügeln könnte und anschließend die KE stattfinden könnte. Findet die KE vorher statt, steige ich groß ein.